Source comparison
Melanotan-1 for EPP: Treatment Comparison
Afamelanotide (Melanotan-1) implants α-MSH receptor agonism → eumelanin synthesis 69% increase vs placebo (CUV029 trial: 64.3 hours vs 41 hours) Subcutaneous implant every 60 days during high-UV months Requires clinical insertion; skin darkening permanent unti
This comparison does not assign a generated winner or score.
- Afamelanotide (Melanotan-1) implants
- α-MSH receptor agonism → eumelanin synthesis
- 69% increase vs placebo (CUV029 trial: 64.3 hours vs 41 hours)
- Subcutaneous implant every 60 days during high-UV months
- Requires clinical insertion; skin darkening permanent until implant depletes; nausea in 10–15% of patients
- Gold standard for EPP. Only FDA-approved disease-modifying treatment with Phase 3 efficacy data
- Beta-carotene supplementation
- Quenches singlet oxygen radicals (theoretical)
- No statistically significant improvement in controlled trials
- Oral 120–180mg daily
- Skin discoloration (carotenodermia); inconsistent evidence; abandoned in most modern protocols
- Historically used but lacks robust clinical support. CUV trials excluded beta-carotene comparators for this reason
- Behavioral photoavoidance
- Eliminates light exposure trigger
- 100% effective at preventing phototoxic reactions
- Continuous lifestyle modification
- Severe quality-of-life impact; vitamin D deficiency; social isolation
- Necessary baseline strategy but insufficient as sole management in most patients
- Narrow-band UVB phototherapy
- Induces melanogenesis + epidermal thickening
- Limited data; small case series suggest modest benefit
- 2–3 sessions weekly for 6–8 weeks
- Time-intensive; requires specialized equipment; effect limited to UV-exposed areas
- Experimental approach with minimal evidence. Not a substitute for systemic photoprotection
- Cysteine + oral antioxidants
- Enhances glutathione-mediated ROS scavenging
- No controlled trial data in EPP populations
- Oral supplementation (dose varies)
- Theoretical mechanism unsupported by clinical outcomes
- Biological plausibility exists but clinical translation absent